$1 Million Boost for Brain Cancer Research Enhances Treatment Prospects

Apr 10, 2026, 2:43 AM

Hover over text to view sources

Nova Southeastern University (NSU) in Fort Lauderdale, Florida, has received a significant boost in cancer research funding, with US Representative Debbie Wasserman Schultz successfully securing over $1 million for innovative projects aimed at treating brain cancer. This funding was celebrated during a presentation at the Alan B. Levan | NSU Broward Center of Innovation on April 8, marking a pivotal moment for cancer research at the university.

The newly allocated funds will specifically support groundbreaking research in carbon dot therapy, which presents a novel and non-invasive method for delivering drugs to treat some of the most challenging and inoperable brain cancers. Harry Moon, MD, NSU's president and CEO, emphasized the transformative potential of this investment, stating, "This meaningful investment strengthens our commitment to drive innovation, pursue effective treatments, and provide hope to patients and families in the face of this devastating disease.".

Carbon dot treatment utilizes extremely small, nontoxic carbon nanoparticles—approximately 100,000 times smaller than a human hair. This innovative approach may allow for safer and more cost-effective chemotherapy by enabling lower drug dosages and precise targeting of tumor cells. Initial studies suggest that carbon dot therapy could outperform traditional chemotherapy in destroying brain tumor cells.

A major advantage of carbon dots is their ability to cross the blood-brain barrier, which opens up treatment possibilities for various tumor types, including those that are otherwise inoperable. This advancement signifies a substantial leap towards personalized medicine, allowing clinicians to selectively target tumor cells while reducing adverse side effects.

The research effort will be led by Regina Graham, Ph.D., an associate professor at NSU's Dr Kiran C. Patel College of Allopathic Medicine. The funding will facilitate the acquisition of advanced imaging systems and biomedical equipment necessary for detailed cellular studies of carbon dots, thereby accelerating the development of clinical applications.

Wasserman Schultz expressed her commitment to enhancing community health through such investments, highlighting the urgent need for effective cancer treatments. "As a cancer survivor myself, I'm proud to help provide doctors more medical tools to battle this deadly disease, and to give patients and their families the hope they need to defeat it," she stated.

Brain cancer remains one of the most challenging forms of cancer to treat, with a five-year survival rate of only 33 percent. This is particularly alarming as brain cancer is the leading cause of cancer death among children aged 1 to 14 years. Florida, notably, has higher rates of brain cancer compared to many other states, with Broward County ranking among the top areas for diagnoses.

In addition to this funding, NSU is advancing its cancer research initiatives with support from various donors, including a recent $1 million donation from the Royal Dames of Cancer Research. The university hosts two major health institutes focused on cancer research, which are dedicated to tackling a range of oncology challenges from glioblastoma to innovative cell therapies.

The commitment to research innovation in brain cancer treatment is echoed by similar funding initiatives across the country. For example, the Mark Foundation for Cancer Research recently announced $4 million in funding for glioblastoma research, highlighting the urgent need for innovative approaches in battling this aggressive cancer type.

As NSU's research initiative unfolds, the hope is that advances in carbon dot therapy will lead to more effective treatments, ultimately improving survival rates and quality of life for brain cancer patients. This funding not only reflects a significant step towards innovative cancer therapies but also underscores the importance of community support and collaboration in advancing medical research.

With the ongoing support and dedication from local representatives, researchers, and philanthropists, the future of brain cancer treatment could see transformative changes that provide new hope for patients and their families.

Illinois MD/PhD Students Innovate Solutions for Medical Challenges

Students in the MD/PhD program at Carle Illinois College of Medicine are at the forefront of medical innovation, using their unique training to tackle significant health challenges. This program combines medical education with advanced scientific research, equipping future physician-scientists to develop solutions in various fields, including surgical robotics and cancer care.

FDA's Updated Criteria for Breakthrough Device Designation

The FDA has revised its guidelines for the Breakthrough Devices Program, emphasizing the importance of health equity and accessibility in device designation. This evolution reflects a broader understanding of how medical technologies can address healthcare disparities while ensuring patient safety and efficacy.

Rocket Pharmaceuticals Secures FDA Approval for Kresladi Therapy

Rocket Pharmaceuticals has received accelerated FDA approval for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder affecting children's immune systems. This milestone not only offers hope for affected families but also positions Rocket for future growth as it prepares to conduct necessary post-marketing trials.

Regeneron Science Talent Search 2026 Awards Over $1.8 Million to Young Innovators

The 2026 Regeneron Science Talent Search honored top high school scientists, awarding more than $1.8 million in prizes. Connor Hill won the top award for his innovative work in computational mathematics, while other finalists explored fields such as neural science and cancer treatment.

UVA Health Joins Global Effort to Innovate Pediatric Cancer Treatments

UVA Health researchers have partnered with an international consortium to develop advanced treatments for childhood cancers. This collaboration aims to address the lack of investment in pediatric drug development and improve outcomes for patients facing aggressive forms of cancer.